CAHHIGH SIGNALFINANCIAL10-K

Cardinal Health reported substantially higher profitability with operating income roughly doubling year-over-year, while simultaneously experiencing a significant decline in operating cash flow generation.

The dramatic improvement in reported profitability contrasts sharply with weakened cash generation, creating questions about earnings quality and the sustainability of the profit expansion. This divergence between income statement performance and cash flow metrics warrants careful scrutiny from investors, particularly given the company's historically stable financial profile as an established healthcare distributor.

Comparing 2025-08-12 vs 2024-08-14View on EDGAR →
FINANCIAL ANALYSIS

Cardinal Health delivered substantially higher profitability with both net income and operating income roughly doubling, while gross profit grew a more modest 10.2%. However, this earnings improvement was accompanied by a concerning 36% decline in operating cash flow to $2.4B and reduced cash balances. The company's balance sheet expanded with total assets growing 18% and inventory increasing 12.5%, while the negative stockholders' equity position improved slightly but remains a structural concern.

FINANCIAL STATEMENT CHANGES
Net Income
P&L
+83.2%
$852.0M→$1.6B

Net income grew 83.2% — bottom-line growth signals improving overall business health.

Operating Income
P&L
+83%
$1.2B→$2.3B

Operating leverage kicking in — revenue growth outpacing cost growth, a hallmark of scaling businesses.

Operating Cash Flow
Cash Flow
-36.3%
$3.8B→$2.4B

Operating cash flow fell 36.3% — earnings quality concerns; investigate working capital changes and non-cash items.

Cash & Equivalents
Balance Sheet
-24.5%
$5.1B→$3.9B

Cash decreased 24.5% — monitor burn rate and upcoming capital needs.

Total Assets
Balance Sheet
+17.7%
$45.1B→$53.1B

Asset base grew 17.7% — expansion through organic growth, acquisitions, or capital deployment.

Total Debt
Balance Sheet
+17.5%
$2.1B→$2.5B

Debt rose 17.5% — additional borrowing for investment or operations; monitor coverage ratios.

Stockholders Equity
Balance Sheet
+13.4%
-$3.2B→-$2.8B

Equity base grew 13.4% — retained earnings accumulation or equity issuance strengthening the balance sheet.

Inventory
Balance Sheet
+12.5%
$15.0B→$16.8B

Inventory built 12.5% — monitor whether demand supports this build or if write-downs may follow.

Gross Profit
P&L
+10.2%
$7.4B→$8.2B

Gross profit expanding — improving pricing power or product mix shift toward higher-margin offerings.

LANGUAGE CHANGES
NEW — 2025-08-12
PRIOR — 2024-08-14
ADDED
The number of the registrant s common shares, without par value, outstanding as of July 31, 2025, was the following: 238,793,647 .
References to fiscal 2026, 2025, 2024, 2023, 2022, and 2021 are to the fiscal years ended June 30, 2026, 2025, 2024, 2023, 2022, and 2021, respectively.
Fiscal 2023 items and discussions of year-over-year comparisons between fiscal 2024 and fiscal 2023 that are not included in this Form 10-K can be found in Management s Discussion and Analysis of Financial Condition and Results of Operations in our Annual Report on Form 10-K for the fiscal year ended June 30, 2024 (the "Fiscal 2024 Form 10-K").
We provide pharmaceuticals and medical products and cost-effective services and solutions that enhance the healthcare system and supply chain efficiency.
We connect patients, providers, payers, pharmacists, and manufacturers for integrated care coordination.
We report our financial results in two reportable segments: Pharmaceutical and Specialty Solutions ("Pharma") segment and Global Medical Products and Distribution ("GMPD") segment.
This segment also provides services to pharmaceutical manufacturers and healthcare providers for specialty pharmaceutical products; provides pharmacy management services to hospitals and operates a limited number of pharmacies, including pharmacies in community health centers; repackages generic pharmaceuticals and over the counter healthcare products; and includes our managed services organization platforms for specialty physician offices.
Global Medical Products and Distribution Segment Our GMPD segment manufactures, sources, and distributes Cardinal Health brand medical, surgical, and laboratory products, which are sold in the United States, Canada, Europe, Asia, and other markets.
This segment also distributes a broad range of medical, surgical, and laboratory products known as national brand products to hospitals, ambulatory surgery centers, clinical laboratories, and other healthcare providers in the United States and Canada.
Our at-Home Solutions operating segment has two main businesses: Edgepark, including ADS, directly providing medical supplies to patients with chronic conditions in the home; and at-Home, a business-to-business distribution service that delivers medical supplies and over-the-counter products to home medical equipment providers, home health and hospice agencies, and e-commerce providers.
REMOVED
The number of the registrant s common shares, without par value, outstanding as of July 31, 2024, was the following: 243,845,343 .
References to fiscal 2025, 2024, 2023, 2022, 2021 and 2020 are to the fiscal years ended June 30, 2025, 2024, 2023, 2022, 2021 and 2020, respectively.
This Form 10-K also includes fiscal 2022 items and discussions of year-over-year comparisons between fiscal 2023 and fiscal 2022.
The periods discussed in this Form 10-K have been revised herein to correct an error identified during the preparation of this Form 10-K, as well as to correct other unrelated immaterial errors.
The revisions ensure comparability across all periods reflected herein.
Please refer to Note 1 of the Notes to the Consolidated Financial Statements for additional information about these corrections.
We provide pharmaceuticals and medical products and cost-effective solutions that enhance supply chain efficiency.
We connect patients, providers, payers, pharmacists and manufacturers for integrated care coordination.
Effective January 1, 2024, we began operating under an updated organizational structure and re-aligned our financial reporting structure under two reportable segments: Pharmaceutical and Specialty Solutions ("Pharma") segment and Global Medical Products and Distribution ("GMPD") segment.
This segment also provides services to pharmaceutical manufacturers and healthcare providers for specialty pharmaceutical products; provides pharmacy management services to hospitals and operates a limited number of pharmacies, including pharmacies in community health centers; and repackages generic pharmaceuticals and over-the-counter healthcare products.
MORE FINANCIAL SIGNALS
CRMHIGHSalesforce significantly increased debt by 71% to $14.4B while simultaneously ac...
2026-03-02
UNHHIGHUNH's operating income plummeted 41% despite 12% revenue growth, indicating seve...
2026-03-02
PFEHIGHPfizer achieved a dramatic 87.3% reduction in total debt from $31.4B to $4.0B, r...
2026-02-26
GILDHIGHGILD dramatically increased R&D spending by 81.5% to $9.1B while introducing new...
2026-02-24
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →